Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Videos

At ARVO 2025, in Salt Lake City, Utah, Peng Shang, PhD, talked about her presentation on how the Y402H polymorphism of Complement Factor H (CFH), a major genetic risk factor for AMD, and chronic oxidative stress affect the lipid profile of retinal pigment epithelial (RPE) cells.

ARVO 2025: Lipid metabolism altered by CFH (Y402H) polymorphism and chronic oxidative stress in iPSC-derived RPE cells

Articles

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

FDA grants Breakthrough Therapy Designation for Tinlarebant

LUMIFY eye drops were initially introduced by Bausch + Lomb in 2018 and remain the only OTC redness relievers that selectively target eye redness with a lower risk of rebound redness and loss of efficacy when used as directed.

Bausch + Lomb launches LUMIFY Preservative Free redness reliever eye drops in the US

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

ARVO 2025: PAVIA 12-month results in nonproliferative diabetic retinopathy

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Watch Dr. Kirk Hou's presentation on Characterization of Pseudofl ow Artifact in OCT Angiography of Macular Edema

Dr. Kirk Hou's PDF presentation can be found here

Dr. Kirk Hou Presentation

Dr. Kirk Hou Presentation

Newsletter